Levin A S
Division of Infectious Diseases, São Paulo University Hospital, Rua Harmonia, Brazil.
Clin Microbiol Infect. 2002 Mar;8(3):144-53. doi: 10.1046/j.1469-0691.2002.00415.x.
Recent studies have highlighted the emergence of infections involving multiresistant Acinetobacter clinical isolates. Sulbactam offers direct antimicrobial activity against Acinetobacter species. Accordingly, co-administration of sulbactam with ampicillin or cefoperazone offers the potential of effective empirical therapy against Acinetobacter and other bacteria such as Enterobacteriaceae in institutions in which they are susceptible. Many in vitro studies have indicated that Acinetobacter remains fully susceptible to ampicillin-sulbactam or cefoperazone-sulbactam. Furthermore, ampicillin-sulbactam has proven clinically effective and well tolerated in the treatment of severe acinetobacter infections, including bacteremia. Therefore, ampicillin-sulbactam is a sensible option for the treatment of life-threatening acinetobacter infections.
近期研究突出了涉及多重耐药鲍曼不动杆菌临床分离株感染的出现。舒巴坦对鲍曼不动杆菌具有直接抗菌活性。因此，在舒巴坦对其敏感的机构中，将舒巴坦与氨苄西林或头孢哌酮联合使用，有可能对鲍曼不动杆菌及其他细菌（如肠杆菌科细菌）进行有效的经验性治疗。许多体外研究表明，鲍曼不动杆菌对氨苄西林-舒巴坦或头孢哌酮-舒巴坦仍完全敏感。此外，氨苄西林-舒巴坦已被证明在治疗包括菌血症在内的严重鲍曼不动杆菌感染方面临床有效且耐受性良好。因此，氨苄西林-舒巴坦是治疗危及生命的鲍曼不动杆菌感染的合理选择。
